The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

Results from the first and second interim analyses of the Phase 3 KEYNOTE-B96 trial were selected for presentation during a Presidential Symposium session at the European Society for Medical Oncology ...

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

Merck & Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclitaxel) with or without Roche Holdings AG’s ...

First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy First ever positive Phase 3 study in ...

Efti plus Keytruda and chemotherapy achieved a 60.8% ORR and 90.2% DCR in advanced NSCLC patients. The combination therapy showed improved ORR across all PD-L1 expression levels compared to historical ...

Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in China, Akeso and Summit Therapeutics’ ivonescimab has shown it can delay ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with ...